Bluejay Diagnostics Director Svetlana Dey Receives 100,000-Share Option Award

What Happened Svetlana Dey, a director of Bluejay Diagnostics, was granted 100,000 derivative share-based awards on August 17, 2026. The Form 4 reports an acquisition (code A) of 100,000 shares at $0.00 (reported value $0) because these are stock option awards rather than immediate common-stock transfers.

Key Details

• Transaction date: 2026-08-17; filing date: 2026-08-18 (filed the next day; appears timely).
• Reported transaction: Grant/award of 100,000 derivative securities (Form 4 code A) at $0.00 per share.
• Exercise/strike price and vesting: Options vest and become exercisable at $2.075 per share on the first anniversary of the grant date, per the footnote.
• Conditions: Options are not exercisable unless and until the U.S. FDA grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device (per footnote).
• Shares owned after transaction: Not specified in the filing.

Context This was a grant of stock-option style awards (derivative securities), not an immediate purchase of common stock. The options are out-of-the-money until exercise at $2.075 and include a conditional exercisability clause tied to FDA clearance of a product, which is a common performance/market-condition provision in biotech equity grants. Such awards are routine for insiders and align incentives but do not reflect a current cash investment by the insider.